An interventional study of A PMT rehabilitation nursing plan and General rehabilitation nursing in Mild Cognitive Impairment (MCI), sponsored by Jinzhou Medical University. Completed at 2 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Jinzhou Medical University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.
Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 130th largest by enrollment of the 191 interventional ones that give a count, is one of 32 that started in 2025, is one of 139 with no phase, and was the 236th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:
Central South University · Sites in China
Ages 18–35
Shanghai University of Sport · Sites in China
Ages 60–80
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Sites in China
Ages 35–80
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Shanghai University of Sport · Sites in China
Ages 65+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
310 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 17 · Phase 4 15
First in 2000; this study’s year is marked. 32 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 110 across the 191 interventional studies, 300 across the 119 observational. Of the 90 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 310 have an industry lead sponsor. The 10 most frequent:
Jinzhou Medical University is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Jinzhou Medical University has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
34 of the studies in Cognitive Dysfunction with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
| NCT06417086ZhanYJClinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers | 2026-11-30 |
| NCT07760415Xiangya Hospital of Central South UniversityEEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes | 2026-12-12 |
| NCT03810794Jian Pei,MDClinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease | 2026-12-30 |
Add all 34 to your calendar (.ics) → With an account.
Among the 310 studies in Cognitive Dysfunction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
With the aging of the population, the number of older adults with mild cognitive impairment (MCI) has increased year by year, which has caused serious social and family burdens. At present, the existing drug treatment effect is limited. Studies show the application value of non-drug treatment in the older adults with mild cognitive impairment. Psychomotor Therapy (PMT) is now widely used in European countries and has formed an independent scientific system. Therefore, this topic pays attention to older adults with mild cognitive impairment, intending to promote cognitive stimulation, using PMT methods to build a rehabilitation nursing plan. Relying on older adults care institutions, older adults with mild cognitive impairment in a certain period were divided into a control group (CG) and an experimental group (EG). Older adults will be engaged in a 12-week PMT rehabilitation nursing plan involving relaxation and breathing exercises, face exercises, hand exercises, and mind exercises to promote cognitive health. SPSS 28.0 software was used to analyze data. The comparison of scores of various scales are based on paired t-test statistical methods. The P value \<0.05 will be considered to indicate statistically significant with 95% confidence interval (CI). The rehabilitation effect of the two groups was evaluated according to cognitive assessments (Montreal Cognitive Assessment, MoCA), psychological assessment (Positive and Negative Syndrome Scale, PANSS), and emotional assessment (Hamilton Depression Rating Scale, HAMD-17; Hamilton Anxiety Rating Scale, HAMA-14) . The expected findings of this study may be useful for cognitive rehabilitation plans for the elderly in care institutions, rehabilitation hospitals, communities, and families.
Introduction Research background In the wake of demographic shifts, China is experiencing the profound effects of an aging population. In 2022, China's population aged 65 and over was estimated to be 196 million, accounting for nearly 13.7% of the total population. With the change in population structure, China faces unprecedented challenges in health care, social welfare, and economic sustainability, which has a profound impact on the aging of the population, and cognitive impairment has become the most prominent problem in an aging society. Studies have shown that the overall prevalence of cognitive impairment in people aged 60 years and above in China is estimated to be 6% (95% CI: 5.8% ~ 6.3%), which increases the pressure on families, caregivers, and the healthcare system, and poses economic challenges to the country.
Similarly, population aging is a general trend around the world. According to the United Nations, by 2050, 1/6 of people in the world will be over 65 years old, compared to 1/11 in 2019. As the number of elderly people increases year by year, the prevalence of cognitive impairment in older adults is also increasing. It is reported that about 5-10% of people over 60 years old in the world suffer from dementia. Dementia is a disease characterized by cognitive decline with memory loss and impaired judgment. It not only affects the quality of life but also puts tremendous pressure on the world's healthcare systems and social support systems. Effective intervention measures are urgently needed to address this public health problem.
Mild Cognitive Impairment (MCI) refers to the prodromal stage of dementia that generally does not severely affect daily functioning, associated with an increased risk for Alzheimer's disease and other dementia. The clinical manifestations of MCI mainly include the decline of memory, language function, attention, executive function, visual-spatial structural function, and calculation ability, as well as sensory impairment and thinking disorder. While not all individuals with MCI will develop dementia. Studies have shown that MCI patients have a much higher risk of developing dementia than people with normal cognition. Early identification and intervention of MCI patients can slow or prevent the progression of dementia, thereby reducing the personal, social, and economic burden of dementia.
In recent years, there has been a large amount of literature in China that explores various aspects of dementia, including risk factors, biomarkers, diagnostic criteria, and intervention strategies. However, there are still some limitations for MCI. The diagnostic criteria and assessment tools for MCI in the Chinese population are still not unified, resulting in differences in prevalence estimates and diagnostic methods in different studies. In addition, there are insufficient longitudinal studies on the progression of MCI to dementia in older adults in China, which limits our exploration of the trajectory of the disease. Similarly, there is still no consensus on the heterogeneity of the MCI population, inconsistent diagnostic criteria, and the best treatment methods. Furthermore, the translation of research findings into clinical practice remains a significant bottleneck, with few evidence-based interventions available for preventing or delaying the onset of dementia among individuals with MCI.
Alzheimer's Disease International has advocated for and funded several studies, including some investigating the effectiveness of pharmacological and non-pharmacological interventions for early dementia. There is a great deal of ongoing research into pharmacological treatments, but traditionally, less research has been done into non-pharmacological treatments. Interventions can be broadly divided into those aimed at modifying the course of the disease, those targeting the cause of the disease, and those controlling the manifestations of the disease. PMT is often considered to fall into the last category because they may help slow cognitive decline, address symptoms related to psychosocially challenging behaviors, and improve quality of life.
Problem statement At present, there is a lot of discussion on MCI and dementia prevention. In addition to drug treatment, non-drug treatment is also a hot issue, such as music therapy, transcranial magnetic stimulation (TMS), light therapy (phototherapy), electrotherapy, acupuncture therapy, Taijiquan, Baduanjin, hyperbaric oxygen therapy (HBOT), memory therapy, etc. At present, most of the non-drug treatments target a relatively single cognitive domain, and it is difficult to solve the decline of multiple cognitive domains with one therapy. It still needs more research and discussion.
PMT is not a traditional biological model, but a kind of rehabilitation therapy under the biological-psychological-social model, which focuses on the concept of integrity. It is not focused on motor functions, but on motor skills in relationships, and is related to emotional, sensory, and cognitive functions. By mobilizing the initiative of dementia patients, stimulating their own weakened function, and assisting with personalized PMT treatment plans, a better effect of rehabilitation nursing treatment is achieved. Few published literature has applied PMT theory to the rehabilitation treatment of older adults with MCI, and the intervention plans are not uniform. At present, PMT therapy just started in China. Is it effective for older adults with MCI in China? Which group is it applicable to? Do older adults and their families accept them? There are few studies on it.
The purpose of this study is to develop a PMT rehabilitation nursing plan and evaluate the effectiveness of the rehabilitation nursing plan in older adults with MCI. The findings of this study may be useful for future studies and provide useful reference for nursing care homes, rehabilitation hospitals, communities, and families.
Research Question(s)
Objective General: This study aimed to develop a psychomotor rehabilitation nursing plan and elucidate the effect of the PMT rehabilitation nursing plan among older adults with mild cognitive impairment in promoting cognitive function.
Specific:
Methodology Description of methodology
iii) Target population: Jinzhou Comprehensive Elderly Care Institution and Rehabilitation Center, Liaoning Province.
iv) Sampling frame: List of members from the two elderly care institution and rehabilitation center; Jinzhou Pension Comprehensive Service Center (JPCSC), and Jinzhou Rehabilitation Hospital (JRH), Liaoning Province.
The data collection form was created by the researcher to record general information about older adults, such as age, gender, education level, family history of dementia, marital status, personal annual income, chronic disease. It will take no more than 5 minutes. Then, It will conduct questionnaire surveys before the intervention (baseline) and after the intervention (12 weeks). The questionnaires involved include Montreal Cognitive Assessment (MoCA), which has 11 questions and takes about 10 minutes; Positive and Negative Syndrome Scale (PANSS), which has 30 questions and takes about 20 minutes; Hamilton Anxiety Rating Scale (HAMA-14), which has 14 questions and takes about 10 minutes; Hamilton Depression Rating Scale (HAMD-17), which has 17 questions and takes about 15 minutes. All questionnaires will take no more than 60 minutes. Due to ethical issues, the names of the elderly participating in this study are only used for data collection, and their identity information will not be disclosed.
Data entry and analysis will be performed using SPSS 28.0 software. Descriptive statistics will be used to summarize the general information of older adults. Numerical data will be presented as mean (SD) or median (IQR) based on their normality distribution. Categorical data will be presented as frequency (%). The comparison of scores of various scales are based on paired t-test statistical methods. The P value \<0.05 will be considered to indicate statistically significant with 95% confidence interval (CI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Older adults will be engaged in a 12-week PMT rehabilitation nursing plan involving 2 phases of relaxation and breathing exercises, face exercises, hand exercises and mind exercises to promote cognitive health.
Behavioral: A PMT rehabilitation nursing plan
The control group will be given a standard health education on cognitive health.
Behavioral: General rehabilitation nursing
Older adults will be engaged in a 12-week PMT rehabilitation nursing plan involving 2 phases of relaxation and breathing exercises, face exercises, hand exercises and mind exercises to promote cognitive health. Phase 1 (Weeks 1-6): Includes relaxation and breathing exercises (10 minutes), facial exercises (10 minutes), bead maze activities (10 minutes), geometric shape puzzles (10 minutes), and finger exercises (20 minutes). Phase 2 (Weeks 7-12): Includes relaxation and breathing exercises (10 minutes), Tai Chi ball exercises (10 minutes), screw and nut assembly activities (10 minutes), tangram puzzles (10 minutes), and upper limb music exercises (20 minutes). The experimental group will be given interventions, twice a week every Tuesday and Thursday 9-10 am along with the study intervention.
The control group will be given a standard health education on cognitive health.
Cognitive assessment
The cognitive status of older adults will be assessed by the Montreal Cognitive Assessment (MoCA) scale. Developed by Nasreddine et al. in Canada with reference to the MMSE, the MoCA evaluates multiple cognitive domains, including attention, executive function, memory, language, visuospatial skills, abstract thinking, calculation, and orientation, making it suitable for a comprehensive assessment of various types of cognitive impairment. The Montreal Cognitive Assessment (MoCA) scale has a minimum score of 0 and a maximum score of 30, with higher scores indicating better cognitive function (e.g., scores near 30 reflect normal cognition), while lower scores suggest greater cognitive impairment. In Western countries, a cutoff score of 26 is commonly used to identify MCI.The results below 26 typically warrant clinical concern, though individuals with ≤12 years of education often receive a +1 point adjustment to their total score.
Time frame: From baseline (pre-intervention) to the end of the intervention (after-intervention) at 12 weeks.
Psychological assessment
The psychological of older adults will be assessed by the Positive and Negative Syndrome Scale (PANSS), including the positive scale (7 items, 7\~49 points), the general psychopathology scale (16 items, 16\~112 points), and the negative scale (7 items, 7\~49 points). The higher the score is, the worse the rehabilitation. The Positive and Negative Syndrome Scale (PANSS) has a minimum score of 30 (indicating absence of all measured symptoms) and a maximum score of 210 (representing severe pathology across all items). Higher PANSS scores indicate worse clinical outcomes, reflecting greater severity of psychotic symptoms-where elevated scores correlate with more pronounced positive symptoms (e.g., delusions/hallucinations), negative symptoms (e.g., social withdrawal), and general psychopathology (e.g., anxiety/impulsivity). Scores above 60 typically suggest clinically significant psychosis, with severe impairment often indicated by scores exceeding 120.
Time frame: From baseline (pre-intervention) to the end of the intervention (after-intervention) at 12 weeks.
Emotional assessment
The emotional assessment will be assessed by the Hamilton Depression Rating Scale (HAMD-17), which is among the most widely used scales for evaluating emotional status. HAMD-17 covers despair, somatization symptoms, sleep disorders, and anxiety. The Hamilton Depression Rating Scale (HAMD-17) has a minimum score of 0 (indicating no depressive symptoms) and a theoretical maximum score of 52 (though practical maxima rarely exceed 50 due to scoring constraints), with higher scores representing worse clinical outcomes-specifically greater severity of depression symptoms such as low mood, guilt, insomnia, psychomotor retardation, and suicidal ideation, where scores ≥8 suggest mild depression, ≥17 indicate moderate depression, and ≥23 reflect severe depression. The 2025 Expert Consensus on Neuropsychological Assessment of Mild Cognitive Impairment recommends the use of these scales, as they effectively identify and quantify depressive and anxiety symptoms in patients with MCI.
Time frame: From baseline (pre-intervention) to the end of the intervention (after-intervention) at 12 weeks.
Emotional assessment
The emotional assessment will be assessed by the Hamilton Anxiety Rating Scale (HAMA-14), which are among the most widely used scales for evaluating emotional status. The Hamilton Anxiety Rating Scale (HAMA-14) ranges from a minimum score of 0 (indicating no anxiety symptoms) to a maximum score of 56 (reflecting the most severe anxiety across all items), with higher scores signifying worse clinical outcomes-specifically greater severity of anxiety-related symptoms such as tension, fears, insomnia, and autonomic hyperactivity, where scores ≥14 typically indicate clinically significant anxiety warranting intervention, and scores \>25 suggest severe impairment. The 2025 Expert Consensus on Neuropsychological Assessment of Mild Cognitive Impairment recommends the use of these scales, as they effectively identify and quantify depressive and anxiety symptoms in patients with MCI.
Time frame: From baseline (pre-intervention) to the end of the intervention (after-intervention) at 12 weeks.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data will not be shared because the approved study protocol restricts the data to use within this study, and secondary use would require additional participant consent.
Ran from Oct 2025 to primary completion in Jan 2026, 3 months.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 3 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jinzhou Medical University